Literature DB >> 20821752

Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo.

Charlotte Ngô1, Carole Nicco, Mahaut Leconte, Christiane Chéreau, Sylviane Arkwright, Marie-Cécile Vacher-Lavenu, Bernard Weill, Charles Chapron, Frédéric Batteux.   

Abstract

Endometriosis affects 6-10% of women in their reproductive years, causing chronic pelvic pain and infertility. Its pathogenesis remains poorly understood and current treatments, based on hormonal therapy or surgery, are often insufficient. The purpose of our study was to investigate the role of the ERK pathway in the development of endometriosis and to test the effects of protein kinase inhibitors on the proliferation of endometriotic cells in vitro and in vivo. We studied ex vivo human endometrial and endometriotic cells in culture. Stromal and epithelial cells were extracted from endometrial and endometriotic biopsies from patients with endometriosis and from patients without endometriosis. The ERK pathway was explored by western blot on cell lysates and by ELISA on total crushed specimens of endometrium. Cells in culture were treated with A771726, PD98059, and U0126. Human endometriotic lesions were implanted in nude mice. Mice were treated with A771726, leflunomide, PD98059, U0126 or PBS during 2 weeks before sacrifice and extraction of the endometriotic implants for histological examination. We found that the ERK pathway was significantly activated in endometriotic cells and in endometrial cells from patients with endometriosis compared to endometrial cells of control patients, both by ELISA and by western blot. This phenomenon was associated with an increased proliferation of endometriotic cells compared to endometrial cells. Treating endometriotic cells with A771726, PD98059 or U0126 abrogated the phosphorylation of ERK and significantly decreased the cellular proliferation in vitro. In vivo, A771726, leflunomide, PD98059, and U0126 controlled the growth of endometriotic implants in the mouse model of endometriosis. Our study shows that protein kinase inhibitors could be new candidates to treat endometriosis. However, further studies are needed to evaluate their effects and tolerability in humans. Copyright 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20821752     DOI: 10.1002/path.2756

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice.

Authors:  Mahaut Leconte; Carole Nicco; Charlotte Ngô; Christiane Chéreau; Sandrine Chouzenoux; Wioleta Marut; Jean Guibourdenche; Sylviane Arkwright; Bernard Weill; Charles Chapron; Bertrand Dousset; Frédéric Batteux
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

2.  Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis.

Authors:  Shengtao Zhou; Tao Yi; Rui Liu; Ce Bian; Xiaorong Qi; Xiang He; Kui Wang; Jingyi Li; Xia Zhao; Canhua Huang; Yuquan Wei
Journal:  Mol Cell Proteomics       Date:  2012-04-09       Impact factor: 5.911

3.  Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France.

Authors:  Peter A W Rogers; Thomas M D'Hooghe; Asgerally Fazleabas; Linda C Giudice; Grant W Montgomery; Felice Petraglia; Robert N Taylor
Journal:  Reprod Sci       Date:  2013-02-20       Impact factor: 3.060

4.  ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.

Authors:  Miles A Miller; Aaron S Meyer; Michael T Beste; Zainab Lasisi; Sonika Reddy; Karen W Jeng; Chia-Hung Chen; Jongyoon Han; Keith Isaacson; Linda G Griffith; Douglas A Lauffenburger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-14       Impact factor: 11.205

5.  Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis.

Authors:  Outi Uimari; Nilufer Rahmioglu; Dale R Nyholt; Katy Vincent; Stacey A Missmer; Christian Becker; Andrew P Morris; Grant W Montgomery; Krina T Zondervan
Journal:  Hum Reprod       Date:  2017-04-01       Impact factor: 6.918

Review 6.  Implications of immune dysfunction on endometriosis associated infertility.

Authors:  Jessica E Miller; Soo Hyun Ahn; Stephany P Monsanto; Kasra Khalaj; Madhuri Koti; Chandrakant Tayade
Journal:  Oncotarget       Date:  2017-01-24

7.  Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis.

Authors:  Tiziana Genovese; Rosalba Siracusa; Ramona D'Amico; Marika Cordaro; Alessio Filippo Peritore; Enrico Gugliandolo; Rosalia Crupi; Angela Trovato Salinaro; Emanuela Raffone; Daniela Impellizzeri; Salvatore Cuzzocrea; Roberta Fusco; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 8.  Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?

Authors:  Luciana Cacciottola; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

9.  Factors and Regional Differences Associated with Endometriosis: A Multi-Country, Case-Control Study.

Authors:  Charles Chapron; Jing-He Lang; Jin-Hua Leng; Yingfang Zhou; Xinmei Zhang; Min Xue; Alexander Popov; Vladimir Romanov; Pascal Maisonobe; Patrick Cabri
Journal:  Adv Ther       Date:  2016-06-24       Impact factor: 3.845

Review 10.  Oxidative Stress and Endometriosis: A Systematic Review of the Literature.

Authors:  Gennaro Scutiero; Piergiorgio Iannone; Giulia Bernardi; Gloria Bonaccorsi; Savino Spadaro; Carlo Alberto Volta; Pantaleo Greco; Luigi Nappi
Journal:  Oxid Med Cell Longev       Date:  2017-09-19       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.